Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Oncternal Therapeutics, Inc. | a17-8825_1ex32d2.htm |
| EX-32.1 - EX-32.1 - Oncternal Therapeutics, Inc. | a17-8825_1ex32d1.htm |
| EX-31.2 - EX-31.2 - Oncternal Therapeutics, Inc. | a17-8825_1ex31d2.htm |
| EX-31.1 - EX-31.1 - Oncternal Therapeutics, Inc. | a17-8825_1ex31d1.htm |
| 10-Q - 10-Q - Oncternal Therapeutics, Inc. | a17-8825_110q.htm |
Exhibit 10.2
2017 Compensation Information for Registrant’s Executive Officers
The table below provides information regarding (i) the base salary of each executive officer of GTx, Inc. (the “Company”), effective as of January 1, 2017 and (ii) the target cash bonus award for Fiscal 2017 for each of the Company’s executive officers under the Company’s Executive Bonus Compensation Plan, expressed as a percentage of applicable base salary:
|
Executive Officer |
|
Title |
|
2017 Annual |
|
2017 Target |
|
|
Marc S. Hanover |
|
Chief Executive Officer |
|
432,649 |
|
65 |
% |
|
Robert J. Wills |
|
Executive Chairman of the Board |
|
220,000 |
|
65 |
% |
|
Henry P. Doggrell |
|
Vice President, Chief Legal Officer and Secretary |
|
378,119 |
|
35 |
% |
|
Diane C. Young |
|
Vice President, Chief Medical Officer |
|
178,500 |
|
35 |
% |
|
Jason T. Shackelford |
|
Vice President, Finance and Accounting and principal financing and accounting officer |
|
231,000 |
|
35 |
% |